07:00 , Jun 14, 2010 |  BC Week In Review  |  Financial News

Precision Therapeutics completes venture financing

Precision Therapeutics Inc. , Pittsburgh, Pa.   Business: Pharmacogenetics   Date completed: 5/25/10   Type: Venture financing   Raised: $35 million   Investors: Bain Capital; Hillman Co.; Adams Capital Management Inc.; Birchmere Ventures; Longitude Capital...
00:57 , Jun 12, 2010 |  BC Extra  |  Top Story

Precision raises $35 million

Precision Therapeutics Inc. (Pittsburgh, Pa.) raised $35 million in a series D round led by new investor Bain Capital. Hillman Co., also a new investor, joined existing investors Adams Capital Management; Birchmere Ventures; Longitude Capital...
07:00 , May 17, 2010 |  BioCentury  |  Finance

Financial Engineering Payoff

Profitable cardiovascular and pulmonary company Ikaria Inc. filed for an IPO on Friday last week to raise up to $200 million. Ikaria markets INOmax nitric oxide for inhalation to treat term and near-term infants with...
08:00 , Nov 9, 2009 |  BC Week In Review  |  Financial News

Metabolex completes venture financing

Metabolex Inc. , Hayward, Calif.   Business: Endocrine, Metabolic   Date completed: 11/5/09   Type: Venture financing   Raised: $8.6 million   Investors: Alta Partners; Venrock; Versant Ventures; Bay City Capital; VantagePoint Venture Partners; Novo...
02:42 , Nov 11, 2008 |  BC Extra  |  Financial News

Precision raises $43 million

Precision Therapeutics (Pittsburgh, Pa.) raised $43 million in a series C round led by new investor Longitude Capital Management. Existing investors Adams Capital Management; Quaker BioVentures; Birchmere Ventures; TVM Capital; and Draper Triangle Ventures also...
01:35 , Jul 25, 2008 |  BC Extra  |  Financial News

NuPathe raises $30 million

NuPathe (Conshohocken, Pa.) raised $30 million in a series B round led by Quaker BioVentures and SR One. Previous investors Safeguard Scientifics; Bay City Capital/Birchmere Ventures; Battelle Ventures; and BioAdvance Ventures also participated in the...
08:00 , Dec 10, 2007 |  BioCentury  |  Finance

Ebb & Flow

Genentech shares hit their lowest level since early 2005 last week, shedding $7.76 (10%) to reach $68.49 and lopping off more than $8 billion of the company's market cap to $72 billion. The dive came...
07:00 , Aug 27, 2007 |  BioCentury  |  Finance

Ebb & Flow

Activist investors enjoyed an immediate pop after PDL BioPharma CEO Mark McDade announced last week that he would resign by year end. The news boosted the shares $2.65 (13%) to $23.81 on the week, while...
07:00 , Apr 23, 2007 |  BioCentury  |  Finance

Ebb & Flow

Gilead (GILD) gave the Street another upside surprise for the first quarter, but the EPS uplift looks to have come from less spending on R&D, rather than unexpectedly high revenue. Indeed, while GILD's quarterly revenue...
00:40 , Apr 20, 2007 |  BC Extra  |  Financial News

Metabolex raises $32 million

Metabolex (Hayward, Calif.) raised $32 million in a series D round led by MPM Capital. New investors AllianceBernstein, Deerfield Capital Management and T. Rowe Price joined existing investors Alta Partners, Bay City Capital, Biotech Turnaround...